{"id":"bevonium","rwe":[],"tags":[{"label":"bevonium","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A03AB13","category":"atc"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"piribenzil","offLabel":[],"synonyms":["bevonium","piribenzil","bevonium metilsulfate","bevonium methyl sulfate","bevonium methylsulfate","piribenzil methyl sulfate"],"timeline":[],"brandName":"Piribenzil","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"bevonium","explanation":"Imagine your body's cells are like locks, and Piribenzil is a key that fits into one of those locks. When it binds to the lock, it can either turn it on or off, depending on the type of lock and the key's shape. This can help regulate various bodily functions, but more research is needed to understand how Piribenzil works and what effects it might have on the body.","oneSentence":"Piribenzil is thought to work by interacting with a specific molecular target, although the exact nature of this interaction is not well understood.","technicalDetail":"Piribenzil's mechanism of action is believed to involve the inhibition of a specific enzyme or receptor, although the precise molecular details of this interaction are currently unknown."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Tripelennamine","title":"Tripelennamine","extract":"Tripelennamine, sold under the brand name Pyribenzamine by Novartis, is a drug that is used as an antipruritic and first-generation antihistamine. It can be used in the treatment of asthma, hay fever, rhinitis, and urticaria, but is now less common as it has been replaced by newer antihistamines. The drug was patented at CIBA, which merged with Geigy into Ciba-Geigy, and eventually becoming Novartis.","wiki_history":"==History==\nTripelennamine was patented in 1946 by Carl Djerassi and colleagues, working at CIBA in New Jersey.","wiki_society_and_culture":"==Society and culture==\n\n===Availability===\nTripelennamine is available in the United States under the brand name PBZ OTC."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3024","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BEVONIUM","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Tripelennamine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T09:03:02.962554","biosimilars":[],"competitors":[{"drugName":"glycopyrronium bromide","drugSlug":"glycopyrronium-bromide","fdaApproval":"1961-08-11","relationship":"same-class"},{"drugName":"oxyphenonium","drugSlug":"oxyphenonium","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"propantheline","drugSlug":"propantheline","fdaApproval":"1953-04-02","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"methanthelinium","drugSlug":"methanthelinium","fdaApproval":"1951-07-03","relationship":"same-class"},{"drugName":"tridihexethyl","drugSlug":"tridihexethyl","fdaApproval":"1954-09-15","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"isopropamide","drugSlug":"isopropamide","fdaApproval":"1957-10-09","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"hexocyclium","drugSlug":"hexocyclium","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mepenzolate","drugSlug":"mepenzolate","fdaApproval":"1956-11-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"diphemanil","drugSlug":"diphemanil","fdaApproval":"1976-05-17","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"bevonium","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"glycopyrronium-bromide","brandName":"glycopyrronium bromide","genericName":"glycopyrronium bromide","approvalYear":"1961","relationship":"same-class"},{"drugId":"oxyphenonium","brandName":"oxyphenonium","genericName":"oxyphenonium","approvalYear":"","relationship":"same-class"},{"drugId":"propantheline","brandName":"propantheline","genericName":"propantheline","approvalYear":"1953","relationship":"same-class"},{"drugId":"methanthelinium","brandName":"methanthelinium","genericName":"methanthelinium","approvalYear":"1951","relationship":"same-class"},{"drugId":"tridihexethyl","brandName":"tridihexethyl","genericName":"tridihexethyl","approvalYear":"1954","relationship":"same-class"},{"drugId":"isopropamide","brandName":"isopropamide","genericName":"isopropamide","approvalYear":"1957","relationship":"same-class"},{"drugId":"hexocyclium","brandName":"hexocyclium","genericName":"hexocyclium","approvalYear":"","relationship":"same-class"},{"drugId":"mepenzolate","brandName":"mepenzolate","genericName":"mepenzolate","approvalYear":"1956","relationship":"same-class"},{"drugId":"diphemanil","brandName":"diphemanil","genericName":"diphemanil","approvalYear":"1976","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"34B0471E08","CHEBI":"CHEBI:135495","INN_ID":"2456","UMLSCUI":"C0053533","ChEMBL_ID":"CHEMBL1882461","DRUGBANK_ID":"DB13542","PUBCHEM_CID":"31800","SECONDARY_CAS_RN":"5205-82-3","MESH_SUPPLEMENTAL_RECORD_UI":"C000002"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A03AB13","allCodes":["A03AB13","A03CA06","A03DA03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piribenzil, also known as Bevonium, is a small molecule drug of the bevonium class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of Piribenzil is unclear, with no information available on its patent status, generic manufacturers, or off-patent status. Further research is needed to understand the potential uses and safety considerations of this compound. As a result, Piribenzil is not a commercially available treatment option at this time.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}